461-470 of 1,790 results

  • The Public Weighs In On Medicare Drug Negotiations

    Feature

    This data note from the latest KFF Health Tracking Poll explores the public's views on Medicare drug price negotiation, including how arguments on both sides impact support and opposition; confidence in leaders to do the right thing on drug pricing; and experiences with prescription drug costs.

  • Questions about Prescription Drug Importation? KFF Has Answers

    News Release

    With lowering prescription drug costs a top priority for Americans, the Trump Administration, presidential candidates, members of Congress, and several states are proposing to allow the importation of drugs from abroad, chiefly Canada. The idea of allowing drugs to be imported from Canada and other countries is popular with Americans across the political spectrum, but has yet to be implemented due to concerns about safety, and strong opposition from the drug industry. A new KFF…

  • Abortion Decision Renews Questions About Employer Access to Health Information

    Policy Watch

    This Policy Watch takes a look at employers ability to access abortion information when their health plan covers abortion services. With some states criminalizing entities who assist in abortions, employers and providers face legal jeopardy and existing privacy laws such as HIPAA (the Health Insurance Portability and Accountability Act) may be limited in their privacy protections.

  • Changing COVID-19 Booster Policies and Florida’s Decision to End Vaccine Mandates Create Confusion — The Monitor

    Feature

    This volume explores confusion around COVID-19 booster eligibility as federal recommendations shift and conflicts with guidance from physician organizations; Florida’s decision to end school vaccine mandates; and research demonstrating that artificial intelligence chatbots can provide generally sound advice, but struggle to make personalized recommendations.

  • Key Facts on Abortion in the United States

    Issue Brief

    This issue brief answers some key questions about abortion in the United States and presents data collected before and new data that has been published since the overturn of Roe v. Wade.

  • How Many Adults with Private Health Insurance Could Use GLP-1 Drugs

    Issue Brief

    More than two in five (42%) or 57.4 million adults under 65 with private insurance could be eligible under clinical criteria for GLP-1 drugs used to treat people with type 2 diabetes, obesity, or excess weight and weight-related health issues, according to a new KFF analysis. Though only about 3% of adults with employer coverage had a prescription in 2022, demand for and spending on GLP-1 drugs has grown and could continue to grow. Given…

  • Abortion Trends Before and After Dobbs

    Issue Brief

    This brief reviews the different sources of abortion data in the United States, the factors that have affected abortion rates across the U.S, before and after Roe v. Wade, and what we may see as the Trump administration, Republican majorities in the House and Senate, and a conservative federal judiciary shape policy in the coming years.

  • Strategies To Lower Drug Costs Top the Public’s Health Priorities for Congress

    News Release

    Against the backdrop of public concern about inflation and rising gas prices, proposals to lower what people pay out-of-pocket for drugs tops the public’s list of health care priorities for Congress, a new KFF Health Tracking Poll finds. Most (55%) of the public say inflation is the biggest problem facing the country. Fewer cite other issues such as the Russian invasion of Ukraine (18%), climate change (6%), the COVID-19 pandemic (6%), and crime (6%). The…